Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Patients with (RRMM) and extramedullary disease (EMD) represent a particularly high-risk population with historically poor outcomes. In a new phase 2 analysis presented at the European Hematology ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.